Updates in Cancer Therapies: Moving Forward with A Review of the Latest Data
Event Ended
This event has ended. Registration is no longer available.
Event Schedule
Event Overview
2026 Updates in Cancer Therapies (UCT): Moving Forward with a Review of the Latest Data is a comprehensive live CE event designed to deliver timely, practice-changing updates in oncology. This two-day in-person meeting held January 9 10, 2026, at the Hilton Aventura Miami Hotel in Aventura, Florida, will feature expert-led sessions, panel discussions, and interactive Q&A segments. UCT 2026 brings together leading oncology experts to deliver the most critical updates from ASCO, ESMO, and other major meetings, translating the latest data into practical, patient-centered care strategies. The agenda spans advances across lung, breast, prostate, and colorectal cancers, other solid tumors, and hematologic malignancies such as chronic lymphocytic leukemia, B-cell and T-cell non-Hodgkin lymphomas, and multiple myeloma. Sessions will also highlight emerging technologies such as circulating tumor DNA (ctDNA) and its integration into modern oncology practice. Developed by an expert educational committee with input from past participant evaluations, UCT 2026 aims to foster critical thinking, enhance clinical decision-making, and promote multidisciplinary and interprofessional approaches to patient-centered cancer care. TARGET AUDIENCE This activity is intended for medical oncologists, radiation oncologists, surgical oncologists, oncology nurses, advanced practice providers (NPs, PAs), pharmacists, and other healthcare professionals involved in the care of patients with cancer. LEARNING OBJECTIVES Upon completion of this activity, participants should be better able to: Integrate novel frontline therapies for solid tumors and hematologic malignancies based on the latest regulatory approvals into clinical practice. Utilize liquid biopsy and other novel diagnostic technologies to enhance cancer diagnosis, monitor response, and detect mechanisms of resistance. Identify key oncogenic pathways and biomarkers to inform the development and selection of targeted therapeutic strategies. Differentiate emerging immunotherapy approaches, including combination regimens with chemotherapy, radiotherapy, and biological agents, to optimize treatment outcomes. Recognize and manage common adverse events associated with newly approved oncology therapies to improve patient safety and care.
Instructions for Credit
Thank you for attending this conference. Your feedback is valuable to us.
To receive your Certificate of Attendance, complete and submit the Evaluation Form. Once this form is submitted your certificate will be available for download.
Registered attendees can earn a maximum of 9.00 CME/ABIM MOC/CE credits. You will be able to select the amount of credits being claimed.
Physicians: If you would like to earn MOC credit please complete the Post-Test prior to submitting the evaluation. Once submitted, you will not be able to go back to complete the Post-Test. In order for MEC to report your MOC credit, your ABIM Diplomate ID number and date of birth (mm/dd/yyyy) MUST be included in your MyMedflix user profile. A completed evaluation and passing score of 70% on the post-test is required. You will have (3) attempts to pass the test.
Pharmacists: NABP e-profile number and date of birth (mm/dd/yyyy). Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
For questions regarding credit for this activity, please contact MEC at info@meccinc.com. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Credits
- AMA PRA Category 1 Credit™9.00
- AAPA Category 19.00
- IPCE Credits9.00
- Nursing9.00
- Pharmacy9.00
Universal Activity Number(s)
Pharmacist: JA4008179-0000-26-001-L01-P
Event Details
- Duration
- 9.00 hours
- Start Date
- January 9th, 2026 1:00 PM (EST)Central: January 9th, 2026 12:00 PMMountain: January 9th, 2026 11:00 AMPacific: January 9th, 2026 10:00 AM
- End Date
- January 10th, 2026 3:35 PM (EST)Central: January 10th, 2026 2:35 PMMountain: January 10th, 2026 1:35 PMPacific: January 10th, 2026 12:35 PM
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
No Faculty or Disclosure
Disclosure
Accreditation
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 9.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physician
The Medical Educator Consortium designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit."
Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)
Nursing
The Medical Educator Consortium designates this activity for 9.0 ANCC contact hours. ILNA Coding: The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
Care Continuum (OCN, CBCN, CPHON, A0CNP, ROCN): 7.5 points*
Care of the Pediatric Hematology and Oncology Patient (CPHON): 3.75 points*
Diagnosis and Staging (CBCN): 3.75 points*
Oncology Nursing Practice (OCN): 3.25 points*
Foundations of Transplant/HSCT and Cellular Therapy (TCTCN): 1.25 points*
Multi-modality Therapies (ROCN): 3.75 points*
Nursing Practice (CBCN): 1.5 points*
Oncology Nursing Practice (OCN): 3.75 points*
Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP): 1.5 points*
Treatment (OCN, CBCN, AOCNP, CPHON, ROCN): 3.75 points*
Total Points: 9.0
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated is the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of Nursing Continuing Professional Development (NCPD) awarded from this course and may only apply to the credential each nurse is renewing. Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Pharmacist
This Application-based activity has been approved for 9.0 contact hours (0.900 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-26-001-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
Physician Associate
The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 9.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.